All
Results from preclinical study KIO-104 released
KIO-104 is a therapeutic candidate shown to significantly reduce retinal scar formation.
First patient dosed in VAN-2401 phase 1 clinical trial
The VAN-2401 phase 1 clinical trial will evaluate the use of KH658 for the treatment of wet AMD.
4D Molecular Therapeutics receives RMAT designation for 4D-150 for the treatment of diabetic macular edema
4D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) to be targeted to the retina with a single, well-tolerated intravitreal injection.
ARVO Foundation to give Subrata Batabyal, PhD, 2025 Carl Camras Translational Research Award
Tavo Biotherapeutics announces two new senior leaders
Lukas Scheibler, PhD, and Graham Cooper join Tavo Biotherapeutics and chief research and development officer and chief financial officer.
Cencora to support US rollout of Neurotech's cell therapy, ENCELTO
Neurotech partners with Cencora for the U.S. launch of ENCELTO, the first FDA-approved treatment for MacTel, enhancing patient access and support.
ARVO 2025: Editorial Board Members set to present data
LuxIA receives CE-MDR certification
LuxIA is designed to screen adult diabetic patients for more-than-mild diabetic retinopathy.
FDA grants clearance of OcuMet Beacon
The OcuMet Beacon is a proprietary, noninvasive tool for assessing retinal health. The company said it will be available on the US market for use in clinics and healthcare institutions.
Therini Bio, Inc. shares positive results of Phase 1a trial for THN391
Editorial board members to present at Retina World Congress 2025
May declared as IRD and genetic testing month
Prevent Blindness has declared May the second annual inherited retinal disease and genetic testing month, offering free resources on education and other awareness efforts.
A genetic link between schizophrenia and retinal thinning
A large international study reported a genetic link between schizophrenia and retinal status.
Regeneron to highlight real-world efficacy of aflibercept 8 mg (EYLEA HD) in wAMD, DME, and DR
The company announced 27 abstracts at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting from May 4 to 8 in Salt Lake City.
NIH researchers use AI to improve retinal imaging
Scientists enhance eye imaging with AI, achieving high-resolution views of retinal cells, potentially revolutionizing disease detection and monitoring in clinics.
Neurotech selects Cencora to support the US launch of its cell therapy
Cencora will serve as the exclusive specialty distributor and provide comprehensive commercialization support, including third-party logistics, specialty logistics and patient support services
Daniela Ferrara appointed by Topcon Healthcare as CMO
Topcon Healthcare has appointed Daniela Ferrara, MD, PhD, as chief medical officer to lead the company’s clinical and medical strategy.
Wave of the future: Partnership between eye care and psychology
A two-way foot bridge between eye care and mental health.
Central choroidal thickness: Important biomarker for assessing response to aflibercept in treatment-naive DME
Brazilian researchers used swept-source OCT and OCT-angiography to study the effects of an initial dose of aflibercept on untreated diabetic macular edema in patients.
When the world went virtual: How ophthalmology’s conferences stayed on track
Five years after the COVID-19 pandemic shutdown reshaped how the world gathers, here's how some of ophthalmology’s leading associations are still applying lessons forged in crisis.
A decade of uveitis: Trends in diagnosis and disease progression
Positive topline results from phase 2 VVN461 trial for non-infectious anterior uveitis
VivaVision Biotech reveals promising phase 2 trial results for VVN461, a new treatment for Non-Infectious Anterior Uveitis, showcasing safety and efficacy.
Eye care industry leaders met at the White House to discuss tariff implications
Industry leaders discuss the impact of rising tariffs on vision care costs, advocating for policy changes to ensure affordable access to essential eyewear.
Prototype Oz system stimulates thousands of M cone cells: On the threshold of new ocular experimentation
Novel color created, olo, beyond previous human perception.
Researchers develop virus-like particle to enhance editing proteins causing inherited eye diseases
The first Retina Sunday program debuts at this year's ASCRS and ASOA Annual Meetings
Abby Markward, MBA, executive director of the ASCRS Foundation and the ASOA, provides a sneak peek of the posterior segment-focused event.
Beth Marsh appointed as new Neurotech chief commercial officer
Marsh will begin her role as COO April 28.
Using retinal images to classify metabolic syndrome
Authors defined metabolic syndrome as “the set of factors that increase the risk of cardiovascular disease and diabetes, such as hypertension, central obesity, insulin resistance, and atherogenic dyslipidemia.”
FDA issues CRL for Regeneron's aflibercept 8 mg (Eylea HD) sBLA
The FDA did not agree with a supplemental Biologics License Application for the addition of extended dosing intervals of up to 24 weeks across currently-approved indications.
AI-powered biomarker segmentation enhances precision in monitoring nAMD
Authors of the study believe this potential will provide clinicians with valuable information about patient responses to treatment.
